Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin.

AUTOR(ES)

Seddon, M

RESUMO

The pharmacokinetics of the new cephalosporin Ro-13-9904 were studied in six healthy male volunteers receiving a 500-mg dose as a bolus intravenously. Tissue penetration of the antibiotic was estimated by using a cantharides blister method. The data obtained fitted a two-compartment open model. The mean elimination half-life was about 8 h, which is considerably longer than that of other beta-lactam compounds. The distribution volume was 4.3 liters in the central compartment. Levels of Ro 13-9904 in blister fluid exceeded those in serum after 6.5 h. Approximately 60% of the antibiotic was excreted in the urine.

Documentos Relacionados

• In vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin.
• Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.
• In vitro activity of Ro 13-9904, a new beta-lactamase-stable cephalosporin.
• Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporin.
• Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.